CompletedPhase 2

Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19

Russia116 participantsStarted 2023-09-29

Plain-language summary

AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19. The aim of the Phase II study is to evaluate the safety, neutralizing activity and efficacy of AZD3152 for pre exposure prophylaxis of COVID-19

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Obese, ie, BMI ≥ 30
✓. Congestive heart failure
✓. Chronic obstructive pulmonary disease
✓. Chronic kidney disease
✓. Intolerant of vaccine
✓. Immunocompromised state (one of the following risk factors ):
✓. Have cancer
✓. Have solid organ transplant or a hematopoietic stem cell transplant

What they're measuring

The Number and Proportion of Subjects With AEs, SAEs, MAAEs, AESIs.

Timeframe: up to Day 181

Trial details

NCT IDNCT06057064

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-05-17

Results submitted2025-04-30

View on ClinicalTrials.gov More COVID-19, SARS-CoV-2 trials